Abstract
Etifoxine is an anxiolytic compound structurally unrelated to benzodiazepines and neurosteroids but potentiating GABAA receptor function by a dual mode of action including a direct positive allosteric modulation through a site distinct from that of benzodiazepines. Gabapentin is an antiepileptic drug structurally related to GABA but with a mechanism of action that is still unclear. Methods: Using the four-plate test (FPT) model of anxiety in mice the potential anxiolytic-like effect of gabapentin was first evaluated. In a second part, the effects of both drugs were evaluated in a test retest procedure in the FPT. Results: Gabapentin, for non sedative doses, increased significantly the number of punished passages in the FPT as did etifoxine. In the test -retest procedure, etifoxine (40 and 50 mg.kg) increased the number of shocks accepted by the animal as compared with benzodiazepine. The same effect was observed with gabapentin (32 and 64 mg/kg) with an increase in retested mice responding during the second trial. However, the effect was smaller than that achieved with DOI (a 5-HT2A agonist). Those results are of importance as it was the first time that GABAergic like ligands respond, even weakly, in experienced mice in the FPT. Whether this effect is due to stress or anxiety is open to discussion.
Keywords: Etifoxine, gabapentin, four-plate test, test-retest procedure, stress, anxiety, mice, benzodiazepine, Xenopus oocytes, GABAAR, neocortex, hypothalamus, diazepam, Flumazenil
Current Psychopharmacology
Title: Insight into the Mechanism of the Four-Plate Test-Retest Procedure Using Etifoxine as Compared with Gabapentin
Volume: 1
Author(s): Michel Bourin and Martine Hascoet
Affiliation:
Keywords: Etifoxine, gabapentin, four-plate test, test-retest procedure, stress, anxiety, mice, benzodiazepine, Xenopus oocytes, GABAAR, neocortex, hypothalamus, diazepam, Flumazenil
Abstract: Etifoxine is an anxiolytic compound structurally unrelated to benzodiazepines and neurosteroids but potentiating GABAA receptor function by a dual mode of action including a direct positive allosteric modulation through a site distinct from that of benzodiazepines. Gabapentin is an antiepileptic drug structurally related to GABA but with a mechanism of action that is still unclear. Methods: Using the four-plate test (FPT) model of anxiety in mice the potential anxiolytic-like effect of gabapentin was first evaluated. In a second part, the effects of both drugs were evaluated in a test retest procedure in the FPT. Results: Gabapentin, for non sedative doses, increased significantly the number of punished passages in the FPT as did etifoxine. In the test -retest procedure, etifoxine (40 and 50 mg.kg) increased the number of shocks accepted by the animal as compared with benzodiazepine. The same effect was observed with gabapentin (32 and 64 mg/kg) with an increase in retested mice responding during the second trial. However, the effect was smaller than that achieved with DOI (a 5-HT2A agonist). Those results are of importance as it was the first time that GABAergic like ligands respond, even weakly, in experienced mice in the FPT. Whether this effect is due to stress or anxiety is open to discussion.
Export Options
About this article
Cite this article as:
Bourin Michel and Hascoet Martine, Insight into the Mechanism of the Four-Plate Test-Retest Procedure Using Etifoxine as Compared with Gabapentin, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010002
DOI https://dx.doi.org/10.2174/2211556011201010002 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microendophenotypes of Psychiatric Disorders: Phenotypes of Psychiatric Disorders at the Level of Molecular Dynamics, Synapses, Neurons, and Neural Circuits
Current Molecular Medicine Organotypic Cultures as Tools for Testing Neuroactive Drugs – Link Between In-Vitro and In-Vivo Experiments
Current Medicinal Chemistry Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry A2A Adenosine Receptor and its Modulators: Overview on a Druggable GPCR and on Structure-Activity Relationship Analysis and Binding Requirements of Agonists and Antagonists
Current Pharmaceutical Design Graphical Abstracts:
Central Nervous System Agents in Medicinal Chemistry Commentary [Research Highlights (Making Sense Out of Antisense in Huntington’s Disease)]
CNS & Neurological Disorders - Drug Targets Disruption of Glutamate-Glutamine-GABA Cycle Significantly Impacts on Suicidal Behaviour: Survey of the Literature and Own Findings on Glutamine Synthetase.
CNS & Neurological Disorders - Drug Targets Enantiopure 1,2,3-Triazolyl-β-amino Acids via Click Cycloaddition Reaction on Racemic Alkynyl Precursors Followed by Separation of Stereoisomers
Current Topics in Medicinal Chemistry An Insight into Molecular Mechanisms and Novel Therapeutic Approaches in Epileptogenesis
CNS & Neurological Disorders - Drug Targets The Design of Multi-target Drugs to Treat Cardiovascular Diseases: Two (or more) Birds on One Stone
Current Topics in Medicinal Chemistry Epilepsy, Theories and Treatment Inside Corpus Hippocraticum
Current Pharmaceutical Design Metastasis-Associated Protein S100A4: Spotlight on its Role in Cell Migration
Current Cancer Drug Targets Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Patient-Specific Induced Pluripotent Stem Cell Models in Mitochondrial Diseases
Current Stem Cell Research & Therapy Editorial [Hot Topic: New Ligands at 5-HT and DA Receptors for the Treatment of Neuropsychiatric Disorders (Guest Editor: Giuseppe Di Giovanni) ]
Current Topics in Medicinal Chemistry Neuroprotective Effects of Low-dose Lithium in Individuals at Ultra-high Risk for Psychosis. A Longitudinal MRI/MRS Study
Current Pharmaceutical Design Damaged Proteins Bearing L-Isoaspartyl Residues and Aging: A Dynamic Equilibrium Between Generation of Isomerized Forms and Repair by PIMT
Current Aging Science Valeriana jatamansi Constituent IVHD-valtrate As a Novel Therapeutic Agent to Human Ovarian Cancer: in vitro and in vivo Activities and Mechanisms
Current Cancer Drug Targets The Role of Peripheral Benzodiazepine Receptors (PBRs) in CNS Pathophysiology
Current Medicinal Chemistry Targeting of Peripherally Expressed Pain-Related Molecules in Injury- Induced Chronic Neuropathic Pain
CNS & Neurological Disorders - Drug Targets